What are the AHA/ASA guidelines on the use of hormone therapy in postmenopausal women to prevent stroke?

Updated: Jan 10, 2016
  • Print


In postmenopausal women, neither hormone therapy (conjugated equine estrogen [CEE] with or without medroxyprogesterone) nor selective estrogen receptor modulators (ie, raloxifene, tamoxifen, tibolone) should be used for primary prevention of stroke. [12]

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!